{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T15:05:30Z","timestamp":1766847930006},"reference-count":34,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2020,2,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Chronic Hepatitis C (CHC) is a common progressive healthcare challenge\nthat leads to liver cirrhosis, liver failure, and hepatocellular carcinoma. The optimum therapy was\na combination of pegylated interferon and ribavirin, which was associated with moderate response\nand severe side effects. Sofosbuvir revolutionized CHC treatment, especially in combination with\nother antiviral agents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The aim of this study was to compare and evaluate the safety and efficacy of sofosbuvir\/\ndaclatasvir versus sofosbuvir\/ledipasvir for the treatment of non-cirrhotic na\u00efve patients with\nchronic Hepatitis C Virus (HCV) genotype 4 infection for 12 weeks.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>One hundred CHC genotype 4 patients (70 females, 30 males) were recruited from the\nhepatology clinic at the Beni-Suef general hospital. Patients were randomly allocated into two\ngroups that received a 12 weeks treatment of either sofosbuvir 400 mg\/daclatasvir 60 mg or sofosbuvir\n400 mg\/ledipasvir 90 mg. The sustained virological response 12 weeks post-treatment\n(SVR12) (HCV RNA &lt; Lower Limit of Quantification (LLOQ)) was determined to evaluate efficacy.\nThe clinical laboratory tests and any reported adverse effects starting from the administration\nof the first dose till 30 days after the last dose were assessed to evaluate safety.\nThe main outcome measure was the assessment of the safety, efficacy and compliance of sofosbuvir\/\ndaclatasvir versus sofosbuvir\/ledipasvir for the treatment of non-cirrhotic na\u00efve CHC genotype\n4 patients for 12 weeks.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>The main outcome measure was the assessment of the safety, efficacy and compliance of sofosbuvir\/\ndaclatasvir versus sofosbuvir\/ledipasvir for the treatment of non-cirrhotic na\u00efve CHC genotype\n4 patients for 12 weeks.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>SVR12 was achieved by 98% and 96% of patients receiving sofosbuvir plus ledipasvir\nand sofosbuvir plus daclatasvir, respectively. The most common adverse events reported were\nheadache, and fatigue. No patients discontinued treatment due to adverse events.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The findings from this study suggest that the 12 weeks treatment regimens of sofosbuvir\nplus daclatasvir and sofosbuvir plus ledipasvir were both efficacious and well-tolerated in\npatients with HCV genotype 4 infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Impact on Practice:<\/jats:title>\n<jats:p>In this paper, we report on the most recent approaches in the treatment of\nHepatitis C genotype 4 patients in Egypt. This is significant because this article focuses on comparing\nthe efficacy and tolerability of the most commonly used antiviral drugs in Egypt.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886314666191001151314","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T14:09:59Z","timestamp":1569938999000},"page":"53-60","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ledipasvir\/Sofosbuvir versus Daclatasvir\/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients"],"prefix":"10.2174","volume":"15","author":[{"given":"Lamiaa N.","family":"Abdelaty","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Elnaggar","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira A.","family":"Said","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghda R.S.","family":"Hussein","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40265-014-0179-7","volume":"74","author":"Keating G.M.","year":"2014","unstructured":"Keating G.M.; Vaidya A.; Sofosbuvir: First global approval. Drugs 2014,74(2),273-282","journal-title":"Drugs"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1001\/jamainternmed.2013.12505","volume":"174","author":"McCombs J.","year":"2014","unstructured":"McCombs J.; Matsuda T.; Tonnu-Mihara I.; The risk of long-term morbidity and mortality in patients with chronic hepatitis C: Results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med 2014,174(2),204-212","journal-title":"JAMA Intern Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/apt.12551","volume":"39","author":"Wantuck J.M.","year":"2014","unstructured":"Wantuck J.M.; Ahmed A.; Nguyen M.H.; Review article: The epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014,39(2),137-147","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/hep.22127","volume":"47","author":"Kamal S.M.","year":"2008","unstructured":"Kamal S.M.; Nasser I.A.; Hepatitis C genotype 4: What we know and what we don\u2019t yet know. Hepatology 2008,47(4),1371-1383","journal-title":"Hepatology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.20546\/ijcmas.2016.505.029","volume":"5","author":"Elwan N.","year":"2016","unstructured":"Elwan N.; Elfert A.; Abd-Elsalam S.; Study of hepatic steatosis index in patients with chronic HCV infection. Int J Curr Microbiol Appl Sci 2016,5(5),266-274","journal-title":"Int J Curr Microbiol Appl Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00705-017-3573-0","volume":"163","author":"Abd-Elsalam S.","year":"2018","unstructured":"Abd-Elsalam S.; Sharaf-Eldin M.; Soliman S.; Elfert A.; Badawi R.; Ahmad Y.K.; Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol 2018,163(1),51-56","journal-title":"Arch Virol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(99)06527-7","volume":"355","author":"Frank C.","year":"2000","unstructured":"Frank C.; Mohamed M.K.; Strickland G.T.; The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000,355(9207),887-891","journal-title":"Lancet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2334-2-29","volume":"2","author":"Rao M.R.","year":"2002","unstructured":"Rao M.R.; Naficy A.B.; Darwish M.A.; Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis 2002,2,29","journal-title":"BMC Infect Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jhep.2010.11.016","volume":"54","author":"Khattab M.A.","year":"2011","unstructured":"Khattab M.A.; Ferenci P.; Hadziyannis S.J.; Management of hepatitis C virus genotype 4: Recommendations of an International expert panel. J Hepatol 2011,54(6),1250-1262","journal-title":"J Hepatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/liv.12724","volume":"35","author":"Abdel-Razek W.","year":"2015","unstructured":"Abdel-Razek W.; Waked I.; Optimal therapy in genotype 4 chronic hepatitis C: Finally cured? Liver Int 2015,35(1),27-34","journal-title":"Liver Int"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jgh.12028","volume":"28","author":"Stedman C.A.","year":"2013","unstructured":"Stedman C.A.; Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013,28(1),38-45","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"Bacon B.R.","year":"2011","unstructured":"Bacon B.R.; Gordon S.C.; Lawitz E.; Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011,364(13),1207-1217","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"Poordad F.","year":"2011","unstructured":"Poordad F.; McCone J.; Bacon B.R.; Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011,364(13),1195-1206","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.dld.2004.06.015","volume":"36","author":"Tanamly M.D.","year":"2004","unstructured":"Tanamly M.D.; Tadros F.; Labeeb S.; Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: Study description and 12-month results. Dig Liver Dis 2004,36(11),752-759","journal-title":"Dig Liver Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/apt.13923","volume":"45","author":"Elsharkawy A.","year":"2017","unstructured":"Elsharkawy A.; Fouad R.; El Akel W.; Sofosbuvir-based treatment regimens: Real life results of 14 409 chronic HCV genotype 4 patients in Egypt. Aliment Pharmacol Ther 2017,45(5),681-687","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/B978-0-12-803233-6.00017-5","author":"Kamal S.","year":"2018","unstructured":"Kamal S.;  Hepatitis C Developing Countries 2018,209-246","journal-title":"Hepatitis C Developing Countries"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/HMER.S62014","volume":"8","author":"Pol S.","year":"2016","unstructured":"Pol S.; Corouge M.; Vallet-Pichard A.; Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: From the clinical trials to real life. Hepat Med 2016,8,21-26","journal-title":"Hepat Med"},{"key":"ref=18","first-page":"345","volume":"39","author":"Cha A.","year":"2014","unstructured":"Cha A.; Budovich A.; Sofosbuvir: A new oral once-daily agent for the treatment of hepatitis C virus infection. P 2014,39(5),345-352","journal-title":"P"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","volume":"383","author":"Lawitz E.","year":"2014","unstructured":"Lawitz E.; Poordad F.F.; Pang P.S.; Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 2014,383(9916),515-523","journal-title":"Lancet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"Afdhal N.","year":"2014","unstructured":"Afdhal N.; Reddy K.R.; Nelson D.R.; Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014,370(16),1483-1493","journal-title":"N Engl J Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"Afdhal N.","year":"2014","unstructured":"Afdhal N.; Zeuzem S.; Kwo P.; Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014,370(20),1889-1898","journal-title":"N Engl J Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/hep.21176","volume":"43","author":"Sangiovanni A.","year":"2006","unstructured":"Sangiovanni A.; Prati G.M.; Fasani P.; The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006,43(6),1303-1310","journal-title":"Hepatology"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"Sulkowski M.S.","year":"2014","unstructured":"Sulkowski M.S.; Gardiner D.F.; Rodriguez-Torres M.; Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014,370(3),211-221","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/apt.14428","volume":"47","author":"Omar H.","year":"2018","unstructured":"Omar H.; El Akel W.; Elbaz T.; Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: Real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther 2018,47(3),421-431","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9616234","volume":"2018","author":"Ahmed O.A.","year":"2018","unstructured":"Ahmed O.A.; Safwat E.; Khalifa M.O.; Sofosbuvir plus daclatasvir in treatment of chronic hepatitis c genotype 4 infection in a cohort of Egyptian patients: An experiment the size of Egyptian village. Int J Hepatol 2018,2018","journal-title":"Int J Hepatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/MCG.0000000000000896","volume":"52","author":"Babatin M.A.","year":"2018","unstructured":"Babatin M.A.; Alghamdi A.S.; Albenmousa A.; Efficacy and safety of simeprevir or daclatasvir in combination with sofosbuvir for the treatment of hepatitis C genotype 4 infection. J Clin Gastroenterol 2018,52(5),452-457","journal-title":"J Clin Gastroenterol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"S278","DOI":"10.1016\/S0168-8278(15)30182-3","volume":"62","author":"Fontaine H.","year":"2015","unstructured":"Fontaine H.; Hezode C.; Zoulim F.; LP28: Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the French observational cohort anrs CO hepather. J Hepatol 2015,62,S278","journal-title":"J Hepatol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jceh.2017.06.002","volume":"8","author":"Mehta R.","year":"2018","unstructured":"Mehta R.; Kabrawala M.; Nandwani S.; Safety and efficacy of sofosbuvir and daclatasvir for hepatitis C virus infection in patients with \u03b2-Thalassemia major. J Clin Exp Hepatol 2018,8(1),3-6","journal-title":"J Clin Exp Hepatol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1473-3099(15)00157-7","volume":"15","author":"Kohli A.","year":"2015","unstructured":"Kohli A.; Kapoor R.; Sims Z.; Ledipasvir and sofosbuvir for hepatitis C genotype 4: A proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 2015,15(9),1049-1054","journal-title":"Lancet Infect Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/IDR.S153060","volume":"11","author":"Ahmed O.A.","year":"2018","unstructured":"Ahmed O.A.; Kaisar H.H.; Badawi R.; Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist 2018,11,295-298","journal-title":"Infect Drug Resist"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.1002\/hep.510260721","volume":"26","author":"Davis G.L.","year":"1997","unstructured":"Davis G.L.; Lau J.Y.; Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997,26(3)(Suppl. 1),122S-127S","journal-title":"Hepatology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/hep.27814","volume":"61","author":"Wyles D.","year":"2015","unstructured":"Wyles D.; Pockros P.; Morelli G.; Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015,61(6),1793-1797","journal-title":"Hepatology"},{"key":"ref=33","first-page":"501-5","volume":"10","author":"Al Zaabi A, A.","year":"2017","unstructured":"Al Zaabi A, A.; Hassan N; Strauch C; Al Zaabi M; Shahwan M.; Safety and economic evaluation of patients treated for hepatitis with antiviral daclatasvir and sofosbuvir combined vs. ledipasvir\/ sofosbuvir 90mg\/400mg in a medical institution in the U.A.E. J Pharm Sci Res 2017,10(3),501-5","journal-title":"J Pharm Sci Res"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/ajt.14100","volume":"17","author":"Joharji H.","year":"2017","unstructured":"Joharji H.; Al-Jedai A.; Alkortas D.; Efficacy of generic sofosbuvir and branded daclatasvir compared to sofosbuvir and ledipasvir combination in the treatment of genotype 4 hepatitis C Virus. Am J Transplant 2017,17(Suppl. 3),970-971","journal-title":"Am J Transplant"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T11:33:58Z","timestamp":1582630438000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175239\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886314666191001151314","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}